多参数MRI可解释影像组学模型预测乳腺癌新辅助化疗敏感性及无复发生存
多中心回顾性纳入373例治疗前多参数MRI(T2、DCE、DWI)乳腺癌患者,以Miller-Payne分级1-3级为不敏感、4-5级为敏感。联合临床与影像组学的随机森林模型经SHAP解释,内部验证AUC为0.859,外部验证AUC为0.862,列线图评分≥95提示高敏感概率,评分较低与更差的无复发生存独立相关。
要点
- 联合模型预测NAC敏感性优于单纯临床或影像组学模型,外验证AUC达0.862。
- 列线图评分≥95提示高敏感概率,评分较低者无复发生存更差,报告中可提示风险。
- 关键影像特征为T2序列的sigma_5_0_mm_3D_glcm_DifferenceEntropy,阅片时需关注T2纹理异质性。
核心结论
- 基于治疗前多参数MRI的可解释影像组学-临床联合模型可有效预测乳腺癌新辅助化疗敏感性及无复发生存。
- SHAP提供透明个体化预测,联合模型内部验证AUC为0.859,外部验证AUC为0.862。
研究设计与样本
- 多中心回顾性研究,共纳入373例具有治疗前多参数MRI(T2、DCE、DWI)的乳腺癌患者。
- 以Miller-Payne分级为参考标准,1-3级判为NAC不敏感,4-5级判为敏感。
- 手动分割病灶提取影像组学特征,并与临床变量整合,采用随机森林建模,SHAP进行模型解释。
关键影像表现/征象
- SHAP分析显示T2序列的sigma_5_0_mm_3D_glcm_DifferenceEntropy为最具影响力的影像组学特征。
诊断标准与关键数值
- 联合模型在内部验证集AUC为0.859(95% CI: 0.764-0.954)。
- 外部验证中联合模型AUC为0.862,临床模型AUC为0.643,影像组学模型AUC为0.844。
- 列线图评分≥95预测高NAC敏感概率。
临床应用与阅片要点
- 治疗前多参数MRI联合模型可辅助预测乳腺癌NAC敏感概率,支持个体化治疗决策。
- T2序列纹理异质性相关特征对预测贡献大,阅片时不应忽略T2形态与纹理信息。
- 列线图评分较低提示无复发生存较差,报告中可提示临床加强随访。
局限性
- 回顾性设计,手动分割病灶可能存在观察者间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This study aimed to develop and validate an interpretable model using pretreatment multiparametric magnetic resonance imaging (mpMRI) radiomics and clinical data to predict neoadjuvant chemotherapy (NAC) sensitivity and recurrence-free survival (RFS) in breast cancer. The model was interpreted using the SHapley Additive exPlanations (SHAP) framework to enhance clinical transparency and support individualized treatment planning.
MATERIALS AND METHODS: In this multicenter retrospective study, 373 patients with pretreatment mpMRI (T2, dynamic contrast-enhanced, diffusion-weighted imaging) were enrolled. Patients were classified as NAC-insensitive (Miller-Payne grades 1-3) or sensitive (grades 4-5). Radiomic features from manual segmentations were integrated with clinical variables. A combined model was built using random forest and interpreted via SHapley Additive exPlanations (SHAP). A nomogram score from the model was assessed for RFS using Cox regression.
RESULTS: The combined model achieved an AUC of 0.859 (95% CI: 0.764-0.954) in the internal validation set, outperforming the clinical (AUC 0.643) and radiomics (AUC 0.844) models, with similar performance in external validation (AUC 0.862). SHAP analysis identified sigma_5_0_mm_3D_glcm_DifferenceEntropy_T2 as the most influential feature. A nomogram score ≥95 predicted high sensitivity probability. Lower nomogram scores were independently associated with worse RFS.
CONCLUSION: The interpretable radiomics-clinical model based on pretreatment mpMRI effectively predicts NAC sensitivity and RFS, offering potential to aid personalized treatment decisions. By providing transparent, individualized predictions via SHAP, this tool shows potential for optimizing personalized treatment strategies and reducing unnecessary toxicity.
引用
- Zeng, Zeng, Tang, et al. Multiparametric MRI-Based Interpretable Machine Learning Radiomics Model for Predicting Neoadjuvant Chemotherapy Sensitivity and Recurrence-Free Survival in Breast Cancer. Acad Radiol. 2026. PMID: 42648921. doi:10.1016/j.acra.2026.07.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。